Abstract Ten novel coumarin-based hybrids comprising coumarin–pyrazole ( 7a–e ) and coumarin–quinoline ( 11a–e ) derivatives were synthesized via multistep reactions and characterized spectroscopically. Solvent optimization identified DMF: Ethanol (1:1) with H 2 SO 4 as optimal conditions, achieving 88% yield in 2–3 h. Antimicrobial evaluation against four bacterial strains ( Bacillus subtilis , Staphylococcus aureus , Escherichia coli , Acinetobacter baumannii ) and one fungal strain ( Aspergillus niger ) revealed compound 7a as the most potent (MIC: 25 μg/mL), superior to standard drugs. Antioxidant screening showed that 7a exhibited excellent activity (IC 50 : 20.23 ± 0.29 mg/mL), comparable to that of ascorbic acid. Molecular docking against three target proteins (4WMZ, 5FNR, 4LOL) demonstrated strong binding affinity, with 7b showing the highest docking score (− 9.71186 kcal/mol) against 4WMZ. Notably, compound 7b showed the highest predicted binding affinity in silico, whereas compound 7a demonstrated the superior experimental antimicrobial activity; this discrepancy underscores that docking scores offer predictive, not confirmatory, evidence of biological potency. DFT calculations (B3LYP/6–311++ G(d,p)) elucidated electronic properties, including HOMO–LUMO gap (3.8640 eV), Mulliken charge distribution, RDG, ELF, LOL, thermodynamic parameters, and global reactivity descriptors. In silico ADMET profiling revealed favorable physicochemical and drug-like properties for most derivatives; however, uniformly high predicted genotoxicity scores (> 0.99) and moderate hERG cardiotoxicity liability were identified, highlighting the need for rigorous experimental safety validation prior to further development. This integrated approach establishes coumarin–pyrazole and coumarin–quinoline hybrids as promising multifunctional therapeutic agents with antimicrobial and antioxidant potential.
Shaikh et al. (Wed,) studied this question.